目的 探討丹七軟膠囊聯(lián)合布洛芬治療原發(fā)性痛經(jīng)的臨床療效。方法 選取2020年1月—2021年6月張家港市中醫(yī)醫(yī)院收治的160例原發(fā)性痛經(jīng)患者，按照隨機(jī)數(shù)字表法分為對(duì)照組和治療組，每組各80例。對(duì)照組口服布洛芬緩釋膠囊，于經(jīng)前3 d開(kāi)始服藥，0.3 g/次，2次/d。治療組在對(duì)照組基礎(chǔ)上口服丹七軟膠囊，于經(jīng)前3 d開(kāi)始服藥，5粒/次，3次/d。每個(gè)月經(jīng)周期連服7 d，連續(xù)治療3個(gè)月經(jīng)周期。觀(guān)察兩組的臨床療效，比較治療前后兩組腹痛視覺(jué)模擬評(píng)分法（VAS）評(píng)分、痛經(jīng)癥狀評(píng)分、36項(xiàng)健康調(diào)查簡(jiǎn)表（SF-36）總分，血流變參數(shù)[全血高、低切黏度（HBV、LBV），血漿黏度（PV），紅細(xì)胞比容（HCT）]。統(tǒng)計(jì)兩組不良反應(yīng)情況。結(jié)果 治療后，治療組總有效率是95.00%，較對(duì)照組的85.00%顯著提高（P＜0.05）。治療后，兩組腹痛VAS評(píng)分、痛經(jīng)癥狀評(píng)分均顯著降低，SF-36總分均顯著升高（P＜0.05）；治療后，治療組腹痛VAS評(píng)分、痛經(jīng)癥狀評(píng)分低于對(duì)照組，SF-36總分高于對(duì)照組（P＜0.05）。治療后，兩組HBV、LBV、PV、HCT均顯著降低（P＜0.05）；以治療組下降更顯著（P＜0.05）。治療后，治療組和對(duì)照組不良反應(yīng)發(fā)生率分別是5.00%、3.75%，兩組不良反應(yīng)發(fā)生率比較差異無(wú)統(tǒng)計(jì)學(xué)意義。結(jié)論 丹七軟膠囊聯(lián)合布洛芬治療原發(fā)性痛經(jīng)有確切療效，能有效減輕患者痛經(jīng)相關(guān)癥狀和疼痛程度，提高生活質(zhì)量，改善機(jī)體血液流變性，且患者耐受性較好。

Objective To investigate the clinical efficacy of Danqi Soft Capsules combined with ibuprofen in treatment of primary dysmenorrhea. Methods A total of 160 patients with primary dysmenorrhea admitted to Zhangjiagang Hospital of Traditional Chinese Medicine from January 2020 to June 2021 were selected and divided into control group and treatment group according to random number table method, with 80 cases in each group. Patients in the control group were po administered with Ibuprofen Sustained-release Capsules 3 days before menstruation, 0.3 g/time, twice daily. Patients in the treatment group were po administered with Danqi Soft Capsules on the basis of the control group 3 days before menstruation, 5 grains/time, three times daily. Each menstrual cycle was treated for 7 d, and the treatment lasted for 3 consecutive menstrual cycles. The clinical effect of the two groups was observed, and the visual analogue scale (VAS) score, dysmorrhea symptom score, 36-item health Survey Short Form (SF-36) total score, hemorheological parameters [whole blood high and low shear viscosity (HBV, LBV), plasma viscosity (PV), erythrocyte specific volume (HCT)] were compared between the two groups before and after treatment. The adverse reactions of the two groups were analyzed. Results After treatment, the total effective rate in the treatment group was 95.00%, which was significantly higher than 85.00% in the control group (P < 0.05). After treatment, abdominal pain VAS score and dysmenorrhea symptom score were significantly decreased, and SF-36 total scores were significantly increased in both groups (P < 0.05). After treatment, the scores of abdominal pain VAS and dysmenorrhea symptoms in the treatment group were lower than those in the control group, while the total score of SF-36 in the treatment group was higher than that in the control group (P < 0.05). After treatment, HBV, LBV, PV, and HCT were significantly decreased in both groups (P < 0.05). The decrease was more significant in the treatment group (P < 0.05). After treatment, the incidence of adverse reactions in the treatment group and the control group was 5.00% and 3.75%, respectively, and there was no statistical significance in the incidence of adverse reactions between the two groups. Conclusion Danqi Soft Capsules combined with ibuprofen has definite curative effect in treatment of primary dysmenorrhea, and can effectively reduce dysmenorrhea related symptoms and pain degree, improve the quality of life and the body blood rheology with good tolerance.

R984